PLANTATION, Fla., June 16 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today announced that the Company is scheduled to make two
presentations at the BIO 2005 Annual International Convention, the premier
global biotechnology event of the year, to be held in Philadelphia June 19-22.
Presentation details are as follows:
* Event: BIO Business Forum
Presenter: Charles A. Rice, President & CEO
When: Monday, June 20 at 5:00 p.m.
Where: Pennsylvania Convention Center, Room D
* Event: Animal and Plant Sources for New Biotech Treatments, a BIO-
hosted lunch briefing for patient advocacy groups (Invitation only)
Presenter: Professor William H. Stimson, Ph.D., Director of Research
When: Tuesday, June 21 from 12:00 - 1:30 p.m.
Where: The Philadelphia Marriott
"BIO 2005 is an important event for Viragen to meet with corporate
partnering candidates and make formal presentations that raise our visibility
in the industry and showcase our progress," stated Mr. Rice. "We have
scheduled many meetings in advance with biotechnology and pharmaceutical
executives, research institutions and investors to meet one-on-one and discuss
business opportunities of mutual interest."
About BIO 2005:
The Biotechnology Industry Organization, better known as BIO, was formed
in 1993. BIO's Annual International Convention is the world's largest
biotechnology event. More than 18,000 biotech executives, investors,
journalists, policymakers and scientists from at least 55 countries are
expected to attend this year's convention. The convention will feature more
than 150 panel sessions covering multiple dimensions of biotech, 1,375 Exhibit
Hall displays and a business forum.
About Viragen, Inc.:
Viragen researches, develops and commercializes pharmaceutical products
designed to treat a broad range of viral and malignant diseases. These
protein-based drugs include: Multiferon(R), a natural human alpha interferon,
approved for sale in various international markets; and humanized anti-cancer
monoclonal antibodies. Viragen is also pioneering the development of Avian
Transgenic Technology, with the renowned Roslin Institute, as a
biomanufacturing platform for the large-scale, efficient and economical
production of therapeutic proteins.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "should," "could" or similar expressions. Such forward-
looking statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
http://www.bio.org/events/2005
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Company News On-Call:
http://www.prnewswire.com/comp/638464.html
CONTACT:
Douglas Calder, Director of Communications of
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
